Friedreich Ataxia Trial, Recruiting NCT06865482 Sponsor: Lexeo Therapeutics Condition: Friedreich Ataxia
Back to Friedreich Ataxia

Friedreich Ataxia Trial, Recruiting

NCT06865482
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male or female and are 6 years old or older at the time of signing the consent forms
  • You have been diagnosed with Friedreich's Ataxia (FA), confirmed by both your symptoms and a genetic test showing the specific gene changes linked to FA, and your symptoms started when you were 25 years old or younger
  • You have been confirmed to have thickening of the heart's left pumping chamber (a condition called left ventricular hypertrophy)
  • Your heart's left pumping chamber is still working at least 40% of its normal pumping capacity

Who may not be able to join:

  • You have another type of heart muscle disease, a significant structural heart problem, significant coronary artery disease, or a serious heart valve problem that is not caused by your FA
  • You are currently receiving heart-strengthening medication through a drip (IV), have a mechanical heart pump device, or have previously had a heart transplant
  • You have a reason why you cannot have a cardiac MRI scan — though children under 12 who cannot have the scan without being sedated may still qualify and will have an ultrasound of the heart instead (confirm with trial site)
  • You have previously had any organ transplant
  • You have started a specific heart rhythm treatment called cardiac resynchronization therapy within the past 6 months
  • You have previously received gene therapy or cell therapy of any kind
  • You have diabetes that is not well controlled, shown by a blood sugar level test result of 8% or higher
  • You currently have an active blood cancer or solid organ cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lexeo Clinical Trials, Lexeo Therapeutics

Phone: 212-547-9879

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Lexeo Therapeutics
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇧🇷 Brazil 🇨🇦 Canada 🇨🇿 Czechia 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Characterize cardiac disease presentation and progression among participants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov